Clinical Trial at Cedars-Sinai Suggests Injections of Female Hormone May Reduce Disease Severity in Certain Male Patients
COVID-19 disproportionately affects men compared with women, raising the possibility that a hormone like progesterone may improve clinical outcomes for certain hospitalized men with the disease. New research from Cedars-Sinai published online in the journal Chest supports this hypothesis.
The pilot clinical trial, involving 40 men, is believed to be the first published study to use progesterone to treat male COVID-19 patients whose lung functions have been compromised by the coronavirus. While the findings are promising, larger clinical trials are needed to establish the potential of this experimental therapy, the investigators said.
An imbalance in men’s testosterone levels was linked to the severity of their coronavirus case, a new study has found.
Hypogonadism was 6 times more likely to be found in the coronavirus-groups than the healthy control group. Testosterone levels under 9.2 nmol/L were recorded in 257 corona patients (89.8%), whereas only 42 healthy men (14.9%) tested for such low levels. Overall, the lower testosterone levels predicted higher instances of mortality and critical conditions in the patients.
Editors note: ** We proposed in April 2020 that human hormones were being manipulated by the virus and that there was a noticeable INCREASE in testosterone levels after recovery from COVID-19 infection that lasted for a period of several months **